TY - JOUR
T1 - Psychosexual development and satisfaction in long-term survivors of childhood cancer
T2 - Neurotoxic treatment intensity as a risk indicator
AU - Lehmann, Vicky
AU - Tuinman, Marrit A.
AU - Keim, Madelaine C.
AU - Winning, Adrien M.
AU - Olshefski, Randal S.
AU - Bajwa, Rajinder P.S.
AU - Hagedoorn, Mariët
AU - Gerhardt, Cynthia A.
N1 - Funding Information: Funded by intramural funding from the Research Institute at Nationwide Children's Hospital and a grant from the Dutch Cancer Society (grant RUG2009-4442). Publisher Copyright: © 2017 American Cancer Society Copyright: Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/5/15
Y1 - 2017/5/15
N2 - BACKGROUND: Risk factors for impairment in psychosexual development and satisfaction among adult survivors of childhood cancer are poorly understood. The authors compared psychosexual outcomes between survivors and healthy controls, and tested whether at-risk survivors can be identified by 1) treatment neurotoxicity or 2) diagnosis. METHODS: A total of 144 young adult survivors of childhood cancer and 144 matched controls completed questionnaires regarding psychosexual development, sexual satisfaction, and satisfaction with relationship status. Survivors were aged 20 to 40 years and were 5 to 34 years after diagnosis. Using medical chart data, survivors were divided into non-neurotoxic (48 survivors), low-dose (36 survivors), and high-dose (58 survivors) neurotoxic treatment groups. RESULTS: Apart from having fewer lifetime sex partners, survivors did not appear to differ from controls. However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status. Neurotoxic treatment intensity further distinguished between survivors of brain tumors with and without psychosexual impairment. CONCLUSIONS: The intensity of neurotoxic treatment may be a valuable indicator of risk for psychosexual impairment relative to diagnosis alone. Health care providers should assess romantic/sexual problems among survivors at risk and make referrals if needed. Cancer 2017;123:1869–1876.
AB - BACKGROUND: Risk factors for impairment in psychosexual development and satisfaction among adult survivors of childhood cancer are poorly understood. The authors compared psychosexual outcomes between survivors and healthy controls, and tested whether at-risk survivors can be identified by 1) treatment neurotoxicity or 2) diagnosis. METHODS: A total of 144 young adult survivors of childhood cancer and 144 matched controls completed questionnaires regarding psychosexual development, sexual satisfaction, and satisfaction with relationship status. Survivors were aged 20 to 40 years and were 5 to 34 years after diagnosis. Using medical chart data, survivors were divided into non-neurotoxic (48 survivors), low-dose (36 survivors), and high-dose (58 survivors) neurotoxic treatment groups. RESULTS: Apart from having fewer lifetime sex partners, survivors did not appear to differ from controls. However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status. Neurotoxic treatment intensity further distinguished between survivors of brain tumors with and without psychosexual impairment. CONCLUSIONS: The intensity of neurotoxic treatment may be a valuable indicator of risk for psychosexual impairment relative to diagnosis alone. Health care providers should assess romantic/sexual problems among survivors at risk and make referrals if needed. Cancer 2017;123:1869–1876.
KW - childhood cancer
KW - long-term survivors
KW - neurotoxicity
KW - psychosexual development
KW - sexual satisfaction
UR - http://www.scopus.com/inward/record.url?scp=85012909691&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/cncr.30513
DO - https://doi.org/10.1002/cncr.30513
M3 - Article
C2 - 28165611
SN - 0008-543X
VL - 123
SP - 1869
EP - 1876
JO - Cancer
JF - Cancer
IS - 10
ER -